YMAB - Y mAbs Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

YMAB is currently covered by 8 analysts with an average price target of $18.2. This is a potential upside of $6.29 (52.81%) from yesterday's end of day stock price of $11.91.

Y mAbs Therapeutics's activity chart (see below) currently has 11 price targets and 36 ratings on display. The stock rating distribution of YMAB is 63.33% BUY, 23.33% HOLD and 13.33% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 58.33% with an average time for these price targets to be met of 162.88 days.

Highest price target for YMAB is $26, Lowest price target is $5, average price target is $18.2.

Most recent stock forecast was given by ROBERT BURNS from HC WAINWRIGHT on 13-May-2024. First documented stock forecast 05-May-2020.

Currently out of the existing stock ratings of YMAB, 19 are a BUY (63.33%), 7 are a HOLD (23.33%), 4 are a SELL (13.33%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

22

$10.09 (84.72%)

21

1 months 6 days ago

3/6 (50%)

$9.81 (80.48%)

178

Buy

26

$14.09 (118.30%)

15

3 months 15 days ago

3/5 (60%)

$8.67 (50.03%)

367

Hold

10

$-1.91 (-16.04%)

12

7 months 4 days ago

3/3 (100%)

$4.75 (90.48%)

114

Sell

7

$-4.91 (-41.23%)

7

9 months 28 days ago

2/5 (40%)

$0.71 (11.29%)

149

Sell

5

$-6.91 (-58.02%)

10 months 5 days ago

3/4 (75%)

$-0.62 (-11.03%)

248

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is YMAB (Y mAbs Therapeutics) average time for price targets to be met?

On average it took 162.88 days on average for the stock forecasts to be realized with a an average price target met ratio 58.33

Which analyst has the current highest performing score on YMAB (Y mAbs Therapeutics) with a proven track record?

ETZER DAROUT

Which analyst has the current lower performing score on YMAB (Y mAbs Therapeutics) with a proven track record?

WILLIAM PLOVANIC

Which analyst has the most public recommendations on YMAB (Y mAbs Therapeutics)?

Etzer Darout works at BMO and has 9 price targets and 5 ratings on YMAB

Which analyst is the currently most bullish on YMAB (Y mAbs Therapeutics)?

Peter Lawson with highest potential upside - $59.74

Which analyst is the currently most reserved on YMAB (Y mAbs Therapeutics)?

Michael Ulz with lowest potential downside - -$6.91

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?